Targeting the epidermal growth factor receptor for cancer therapy

Journal of Clinical Oncology

Volumn 20, Issue 18 SUPPL., 2002, Pages

  Mendelsohn, John ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY;

ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CARCINOMA; CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; ENZYME ACTIVITY; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PURIFICATION; THYROID FUNCTION; TRANSGENIC MOUSE; XENOGRAFT;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS;

EID: 0037106273     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (77)

1. Growth stimulation of A431 cells by epidermal growth factor: Identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody
2. Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors
3. Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity
4. Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new born animal
5. Epidermal growth factor receptor-kinase interactions: Co-purification of receptor and epidermal growth factor-enhanced phosphorylation activity
6. Serum-free cell culture: A unifying approach
7. Autocrine secretion and malignant transformation of cells
8. Over-expression of the EGF receptor is a hallmark of squamous cell carcinomas
9. Similarities and differences between the effect of epidermal growth factor and Rous sarcoma virus
10. Purified EGF receptor-kinase interacts specifically with antibodies to Rous sarcoma virus transforming protein
11. Evidence that viral transforming gene products and epidermal growth factor stimulate phosphorylation of the same cellular protein with similar specificity
12. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences
13. Expression cloning of human EGF receptor complementary DNA: Gene amplification and three related messenger RNA products in A431 cells
14. Human epidermal growth factor receptor cRNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells
15. Human epidermal growth factor receptor cDNA is homologous to a variety of RNAs overproduced in A431 carcinoma cells
16. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies
17. Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen
18. HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor
19. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
20. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
21. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model
22. A monoclonal antibody to the human epidermal growth factor receptor
23. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy
24. Clinical trial with escalating doses of the antiepidermal growth factor receptor humanized monoclonal antibody EMD 72 000 in patients with advanced squamous cell carcinoma of the larynx and hypopharynx
25. Use of the anti-EGFR antibody h-R3 in combination with radiotherapy in the treatment of advanced head and neck cancer
26. In vitro and in vivo stability and anti-tumour efficacy of an anti-EGFR/anti-CD3 F(ab′) 2 bispecific monoclonal antibody
27. A phase I trial of the epidermal growth factor receptor (EGFR)-directed bispecific antibody (BsAB) MDX-447 in patients with solid tumors
28. Cytolytic and cytostatic properties of an anti-human Fc gammaRI (CD64) x epidermal growth factor bispecific fusion protein
29. Tyrosine kinase inhibition: An approach to drug development
30. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase
31. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor
32. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition
33. Phase I and pharmacologic study of the OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies
34. A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy in patients (pts) with advanced. EGFR-expressing, non-small cell lung cancer (NSCLC)
35. A phase I dose-escalating study to evaluate the biological activity and pharmacokinetics of PKI166, a novel tyrosine kinase inhibitor, in patients with advanced cancers
36. Combination chemoprevention of intestinal neoplasia
37. The effects of the novel EGFR/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and transformed cell lines
38. A phase I clinical and biomarker study of the novel pan-erB tyrosine kinase inhibitor, CI-1033, in patients with solid tumors
39. The hallmarks of cancer
40. Activated extracellular signal-regulated kinases: Association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-EGF receptor treatments
41. Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin
42. 1
43. 1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody
44. Blockade of receptors for growth factors: An anti-cancer therapy
45. Raf induces TGFbeta production while blocking its apoptotic but not invasive responses: A mechanism leading to increased malignancy in epithelial cells
46. How cells read TGF-beta signals
47. Nuclear targeting of Bax during epidermal growth factor receptor-induced apoptosis in colorectal cancer cells
48. Induction of apoptosis and activation of the caspase cascade by anti-EGF receptor monoclonal antibodies in DiFi human colon cancer cells do not involve the c-jun N-terminal kinase activity
49. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors
50. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice
51. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by anti-angiogenic mechanisms
52. Blockade of epidermal growth factor receptor signaling on tumor cells and tumor associated endothelial cells for therapy of human carcinomas
53. Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice
54. Antitumor effect of antiepidermal growth factor receptor monoclonal antibodies plus cisdiamminedichloroplatinum on well established A431 cell xenografts
55. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies
56. Antitumor activity of paclitaxel in combination with anti-growth factor receptor monoclonal antibodies in breast cancer xenografts
57. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase
58. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225
59. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor
60. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer
61. Efficacy and safety of the anti-epidermal growth factor antibody (EGFR) IMC-C225, in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) refractory to cisplatin containing chemotherapy
62. Final report of the efficacy and safety of the anti-epidermal growth factor antibody Erbitux (IMC-C225), in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) refractory to cisplatin containing chemotherapy
63. Cetuximab (C225) plus cisplatin/carboplatin is active in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) progressing on a same dose and schedule platinum-based regimen
64. Phase III trial comparing cisplatin (C) + placebo to C + anti-epidermal growth factor antibody (EGF-R) C225 in patients (pts) with metastatic/recurrent head & neck cancer (HNC)
65. Final results from a phase II trial of ZD1839 ('Iressa') for patients with advanced non-small-cell lung cancer (IDEAL 1)
66. A phase II trial of ZD1839 ('Iressa') in advanced non-small cell lung cancer (NSCLC) patients who failed platinum- and docetaxel-based regimens (IDEAL 2)
67. A phase 11 study of Erbitux (IMC-C225), an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer (NSCLC)
68. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts
69. Cetuximab (IMC-225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR)
70. Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGF-alpha bigenic mice
71. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells
72. Combinatorial chemoprevention of intestinal neoplasia
73. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck
74. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody
75. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer
76. Safety profile of the monoclonal antibody (MoAb) IMC-C225, an anti-epidermal growth factor receptor (EGFr) used in the treatment of EGFr-positive tumors
77. PD 153035, a tyrosine kinase inhibitor, prevents receptor activation and inhibits growth of cancer cells overexpressing the epidermal growth factor receptor in a dose and receptor number dependent manner